Cancer Drugs– tag –
-
Aging and Cancer Expert Series – Part 8 Geriatric Oncology in Practice: Bringing Aging Biology into Cancer Care
Introduction: The Gap Between Aging Biology and Everyday Oncology In earlier parts of this Expert Series, we have explored: Epigenetic clocks and ImAge as tools to quantify “how old” tissues and cells are Tissue- and genotype-specific pr... -
Aging and Cancer Expert Series – Part 7 Diet, Exercise, Environment, and Geography: External Drivers of Aging × Cancer Risk
Introduction: Adding Lifestyle and Environment to the Genetics–Aging Framework In previous parts of this Expert Series, we focused primarily on “internal” factors: Epigenetic clocks and ImAge as tools to visualize aging Tissue- and genot... -
Aging and Cancer Expert Series – Part 6 Does Aging Always Promote Cancer? Insights from KRAS-Driven Lung Cancer
Introduction: Questioning the Dogma that “Aging = More Cancer” In previous parts of this Expert Series, we have discussed: Tools such as epigenetic clocks and ImAge to “visualize” aging Tissue-specific aging profiles and genetic backgrou... -
Aging and Cancer Expert Series – Part 4 Reproductive Aging and Women’s Cancers: Linking Ovary, Uterus, and Breast Through Hormones and Molecular Networks
Introduction: Reproductive Aging as a Hub Between Women’s Aging and Cancer In Parts 1–3 of the Expert Series, we discussed: Tools to “visualize” aging (epigenetic clocks, single-cell profiles, image-based metrics) Tissue-specific aging p... -
Aging and Cancer Expert Series – Part 3 Cancer as a Driver of Systemic Aging: Immune, Tissue, and Treatment-Related Pathways
Introduction: Beyond “Aging → Cancer” to “Cancer → Aging” In the Introductory and earlier Expert Series articles, we mainly focused on the direction: Aging increases the risk of cancer Tissue- and genotype-specific aging patterns shape w... -
Aging and Cancer Expert Series – Part 2 Tissue-Specific Aging Profiles and Genetic Background: Why Cancer Prefers Certain Organs
Introduction: Aging Is Not Uniform Across the Body In Part 1 of the Expert Series, we focused on “making aging visible” through epigenetic clocks, single-cell analyses, and image-based metrics. We saw that people of the same chronologica... -
Oncology Drug Approval News Flash: FDA grants regular approval to rucaparib for BRCAm mCRPC and approves subcutaneous amivantamab and hyaluronidase-lpuj
FDA approval summary On December 17, 2025, the U.S. Food and Drug Administration (FDA) granted regular approval to rucaparib (Rubraca, pharmaand GmbH) for adult patients with metastatic castration-resistant prostate cancer (mCRPC) associ... -
Oncology Drug Approval News Flash: Fam-trastuzumab deruxtecan-nxki plus pertuzumab approved as first-line therapy for unresectable or metastatic HER2-positive breast cancer
FDA approval summary On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with un... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 5 Lifestyle and Environmental Factors in Aging and Cancer: What Can We Change, and What Is Hard to Change?
Introduction: Deconstructing Risk Factors In Parts 1–4 of this series, we explored aging and cancer from several angles: Time and historical concepts Molecular and genetic mechanisms Immune aging and the tumor microenvironment Organ- and... -
Oncology Drug Approval News Flash: Niraparib plus abiraterone acetate and prednisone approved for BRCA2-mutated metastatic castration-sensitive prostate cancer
FDA approval summary On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adult patients with deleterious or suspected deleteriou... -
Recent ADC Landscape Update Series, Part 3: Merck–Daiichi’s CDH6 ADC R-DXd and DLL3 ADC SHR-4849 – The Next Wave in Ovarian Cancer and SCLC
In Part 3 of this series, we focus on two “second-wave” ADC programs that have attracted considerable attention over the past few months: raludotatug deruxtecan (R-DXd), a CDH6-targeted DXd ADC being co-developed by Daiichi Sankyo a... -
Recent ADC Landscape Update Series, Part 2: Enhertu in Early HER2-Positive Breast Cancer – What DESTINY-Breast05 and 11 Mean for Future Standards of Care
In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-based ADC from AstraZeneca and Daiichi Sankyo that has already transformed the treatment of advanced HER2-positive and HER2-low breast cancer. At ESMO&n... -
Recent ADC Landscape Update Series, Part 1: AstraZeneca’s Post-Enhertu Strategy – In-house ADCs, Radiopharma and Cell Therapy to Redefine Oncology
Around 2025, oncology is entering a new phase in which antibody–drug conjugates (ADCs) sit at the center of a much broader competition for the “next decade” of cancer care. In this series, we review the most important recent clinical dat... -
Oncology Drug Approval News Flash：FDA approves lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma
On December 4, 2025, the U.S. Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol Myers Squibb company), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or ref... -
Oncology Drug Approval News Flash：FDA grants traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory CLL/SLL after covalent BTK inhibitor therapy
On December 3, 2025, the U.S. Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic l... -
Cancer Treatment Introductory–to–Basic Series – Overview
How to Read This 8-Part Series: Seeing the Bigger Picture of Cancer Care The “Cancer Treatment Introductory–to–Basic Series” consists of eight main articles that walk through the big picture of cancer care: overall structure, differences... -
Cancer Treatment Introductory–to–Basic Series – Part 8 (Final)
Life After Treatment and Survivorship: Shaping How You Live With and Beyond Cancer From Part 1 through Part 7 of this series, we have walked through the basics of cancer treatment: overall structure, differences in “curability” among can... -
Oncology Drug Approval News Flash：FDA approves durvalumab (Imfinzi) plus FLOT as perioperative therapy for resectable gastric and GEJ adenocarcinoma
On November 25, 2025, the U.S. Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by sin... -
Cancer Treatment Introductory–to–Basic Series – Part 7
Standard Treatment, Clinical Trials, and Second Opinions: Making Informed Choices In earlier parts of this series, we looked at the overall framework of cancer treatment, differences in “curability” among cancer types, and how to think a... -
Cancer Treatment Introductory–to–Basic Series – Part 5
Cancer-Specific “Curability”: Why Some Cancers Are Harder to Treat In the previous parts of this series, we looked at the overall framework of cancer treatment and introduced the main tools – surgery, drug therapy, radiotherapy, and part...
